West Pharmaceutical Services Overview
West Pharmaceutical Services is a global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable medicines. West Israel (formerly Medimop) focuses on the production of drugs that require mixing two components before use and that are packaged in such a way that they can be used safely in the patient's home. The team in Israel develops and manufactures many well-known West products including the Vial2Bag Admixture systems, the MixJect reconstitution system, Intradermal Adapter product family, Mix2Vial needle-free reconstitution and transfer system, and the SmartDose drug delivery platform, which was launched with commercial success in 2016.
Latest News
growth-positive
Nyxoah Shares Rise on First U.S. Commercial Use of Genio System
Nyxoah has initiated the U.S. commercial rollout of its Genio system, a leadless, battery-free neurostimulation therapy for obstructive sleep apnea (OSA), following FDA approval. The first commercial implants have been successfully performed, indicating strong physician demand and growing payor coverage, including CMS. This milestone marks Nyxoahs transition from a pre-commercial innovator to an active player in the U.S. sleep apnea market. The company is poised for sustained commercial momentum with expanding hospital approvals and trained surgeons. Nyxoahs market capitalization is $168.6 million, and it anticipates an earnings growth of 8.8% in 2026. The Genio system offers a minimally invasive approach, enhancing patient comfort and compliance.
Product StageCustomers
growth-positive
Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy
Entera Bio Ltd. recently presented promising pharmacokinetic data for its oral GLP-2 analog therapy for short bowel syndrome (SBS) at the ESPEN Congress. The therapy, developed in collaboration with OPKO Health, aims to offer a more convenient alternative to existing treatments like Gattex, which require daily injections. The data demonstrated significant pharmacological advantages, including a longer plasma half-life and higher peak plasma concentrations compared to current therapies. While still in preclinical development, the therapys potential to address a market worth nearly $800 million annually could drive positive investor sentiment. The collaboration with OPKO Health is crucial for advancing this innovative treatment.
Product StagePartners
growth-positive
BWAY Shares Gain on FDA Nod for Accelerated Deep TMS Depression Care
BrainsWay Ltd. has received FDA clearance for an accelerated treatment protocol using its Deep Transcranial Magnetic Stimulation (TMS) system, aimed at treating major depressive disorder. This approval is expected to improve patient access and provider flexibility, potentially increasing adoption due to fewer required visits. The companys shares rose by 11.9% following the announcement, and it has seen a 79.2% increase year-to-date. The new protocol, which shortens treatment time significantly, is supported by clinical data showing comparable outcomes to the standard approach. BrainsWay is preparing for provider training and reimbursement updates, positioning this development as a significant growth opportunity in the mental health market.
FDA approved/pending approval
growth-positive
Microbot Shares Rise on FDA Clearance for LIBERTY Robotic System
Microbot Medical Inc. has received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System, marking a significant regulatory milestone. This clearance allows the company to commercialize the LIBERTY system in the U.S. market, aiming to expand its presence in the robotic surgery field. The LIBERTY system is designed to enhance precision and safety in endovascular procedures while minimizing radiation exposure. Following the announcement, Microbots shares surged, reflecting investor confidence in the companys growth prospects. The systems unique design is expected to drive faster adoption, offering a competitive advantage over traditional robotic platforms. Microbot plans to continue gathering clinical data as part of its commercial launch strategy.
Product StageFDA approved/pending approval
growth-positive
BWAY Shares Rise on Strategic Investment in Neurolief's At-Home Care
BrainsWay Ltd. has made a strategic $5 million investment in Neurolief Ltd., a company developing wearable neuromodulation devices for mental health treatment. This investment allows BrainsWay to expand into the at-home treatment market, complementing its existing Deep TMS platform. Neuroliefs Proliv Rx, designed for Major Depressive Disorder, is pending FDA approval. The investment includes a convertible loan with additional funding contingent on FDA approval and revenue milestones. BrainsWays shares have increased following the announcement, reflecting positive market reception. The collaboration aims to diversify revenue streams and strengthen BrainsWays position in the mental health treatment market.
InvestmentPartnersProduct Stage
Team Members
2
Employees: 51-200
Web & Social Links
| Website | www.westpharma.com |
Locations
HaSheizaf 4, Ra'anana, Israel
Photos & Videos
1 item(s)
West Pharmaceutical Services Business
Business models
—
Product stage
—
Employees
51-200
Sector
—Target Customer
—Core Technology
—Tags (6)
packaging-and-containersmedical-devicespharmaceuticalsmedical-equipmentdrug-deliverydigital-healthcareWest Pharmaceutical Services Financials
—
Total funding
—
Capital raised
—
Last funding
—
Funding stage
—
Total rounds
—
Investors
West Pharmaceutical Services Lifecycle
West Pharmaceutical Services News
8 articles
growth-positive
Nyxoah Shares Rise on First U.S. Commercial Use of Genio System
Nyxoah has initiated the U.S. commercial rollout of its Genio system, a leadless, battery-free neurostimulation therapy for obstructive sleep apnea (OSA), following FDA approval. The first commercial implants have been successfully performed, indicating strong physician demand and growing payor coverage, including CMS. This milestone marks Nyxoahs transition from a pre-commercial innovator to an active player in the U.S. sleep apnea market. The company is poised for sustained commercial momentum with expanding hospital approvals and trained surgeons. Nyxoahs market capitalization is $168.6 million, and it anticipates an earnings growth of 8.8% in 2026. The Genio system offers a minimally invasive approach, enhancing patient comfort and compliance.
Product StageCustomers
growth-positive
Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy
Entera Bio Ltd. recently presented promising pharmacokinetic data for its oral GLP-2 analog therapy for short bowel syndrome (SBS) at the ESPEN Congress. The therapy, developed in collaboration with OPKO Health, aims to offer a more convenient alternative to existing treatments like Gattex, which require daily injections. The data demonstrated significant pharmacological advantages, including a longer plasma half-life and higher peak plasma concentrations compared to current therapies. While still in preclinical development, the therapys potential to address a market worth nearly $800 million annually could drive positive investor sentiment. The collaboration with OPKO Health is crucial for advancing this innovative treatment.
Product StagePartners
growth-positive
BWAY Shares Gain on FDA Nod for Accelerated Deep TMS Depression Care
BrainsWay Ltd. has received FDA clearance for an accelerated treatment protocol using its Deep Transcranial Magnetic Stimulation (TMS) system, aimed at treating major depressive disorder. This approval is expected to improve patient access and provider flexibility, potentially increasing adoption due to fewer required visits. The companys shares rose by 11.9% following the announcement, and it has seen a 79.2% increase year-to-date. The new protocol, which shortens treatment time significantly, is supported by clinical data showing comparable outcomes to the standard approach. BrainsWay is preparing for provider training and reimbursement updates, positioning this development as a significant growth opportunity in the mental health market.
FDA approved/pending approval
growth-positive
Microbot Shares Rise on FDA Clearance for LIBERTY Robotic System
Microbot Medical Inc. has received FDA 510(k) clearance for its LIBERTY Endovascular Robotic System, marking a significant regulatory milestone. This clearance allows the company to commercialize the LIBERTY system in the U.S. market, aiming to expand its presence in the robotic surgery field. The LIBERTY system is designed to enhance precision and safety in endovascular procedures while minimizing radiation exposure. Following the announcement, Microbots shares surged, reflecting investor confidence in the companys growth prospects. The systems unique design is expected to drive faster adoption, offering a competitive advantage over traditional robotic platforms. Microbot plans to continue gathering clinical data as part of its commercial launch strategy.
Product StageFDA approved/pending approval
growth-positive
BWAY Shares Rise on Strategic Investment in Neurolief's At-Home Care
BrainsWay Ltd. has made a strategic $5 million investment in Neurolief Ltd., a company developing wearable neuromodulation devices for mental health treatment. This investment allows BrainsWay to expand into the at-home treatment market, complementing its existing Deep TMS platform. Neuroliefs Proliv Rx, designed for Major Depressive Disorder, is pending FDA approval. The investment includes a convertible loan with additional funding contingent on FDA approval and revenue milestones. BrainsWays shares have increased following the announcement, reflecting positive market reception. The collaboration aims to diversify revenue streams and strengthen BrainsWays position in the mental health treatment market.
InvestmentPartnersProduct Stage
growth-positive
Microbot Shares Rise as New U.S. Patent Expands LIBERTY System Market
Microbot Medical Inc. has been granted a new U.S. patent for its LIBERTY Endovascular Robotic System, which enhances its flexibility and broadens its potential applications. This patent expands the companys addressable market from 2.5 million to over six million annual procedures in the U.S., significantly increasing its revenue potential. The patent strengthens Microbots intellectual property portfolio, positioning it for future growth and potential strategic partnerships. While the LIBERTY system is still under FDA review for 510(k) clearance, the patent provides a strategic advantage as the company prepares for commercialization. Following the announcement, Microbots shares rose by 7.1%, and the companys market capitalization is currently $140.7 million.
Product StageFDA approved/pending approval
growth-positive
West Pharma sets up new R&D center, sees Israel as regional hub
West Pharmaceutical Services, Inc. has relocated its Israeli offices to a new location in Raanana. The new office serves as a regional technology center for the companys drug delivery products and as an administrative hub. The companys Israeli team developed a SmartDose drug delivery platform that was approved by the US FDA. The platform is a wearable device that allows patients to self-administer precise doses of medications. West Pharmaceutical Services reported a year-on-year growth of 5.2% in net sales and expects net sales to grow 6 to 8 percent in 2018.
Expand
growth-positive
West Pharmaceutical buys Medimop for $41.8m
West Pharmaceutical Services Inc. has acquired Medimop Medical Projects Ltd. for $36 million in cash, $4 million in shares, and up to $1.8 million of contingent cash consideration. The acquisition is expected to be completed in the third quarter of 2005. Medimop develops disposable medical devices for injectable drugs and its technologies are used in various therapeutic areas. The acquisition is seen as a strategic fit for West Pharmaceutical Services and will enhance its product offerings in the injectable drug market. Medimops founder and president will retain 10% ownership of the company. West Pharmaceutical Services plans to finance the acquisition with bank debt and private lender debt.
Acquisition
West Pharmaceutical Services Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 135 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
West Pharmaceutical Services Internal
Recent Updates
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-05-12 13:47:52.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-05-12 13:48:15.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-08-07 05:43:54.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-05 15:02:53.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-02-13 06:56:18.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-01-25 08:03:55.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-01-25 16:20:26.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-05-12 13:45:26.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-05-12 13:47:52.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-05-12 13:48:15.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-05-12 13:47:52.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-05-12 13:48:15.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-05-12 13:42:17.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-08-07 04:57:21.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-05-12 13:47:52.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-05 14:16:59.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-05 14:43:01.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2018-02-27 11:26:02.000000
Gil Fosh
· gilfosh@gmail.com · Manual · 2018-01-23 13:13:25.000000
Gil Fosh
· gilfosh@gmail.com · Manual · 2018-01-23 13:18:55.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2018-02-27 11:15:15.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2018-02-27 11:16:51.000000
Yamila Silbert
· yamila.urwicz@gmail.com · Manual · 2018-02-27 11:26:31.000000
Gil Fosh
· gilfosh@gmail.com · Manual · 2018-01-23 13:18:19.000000
Gil Fosh
· gilfosh@gmail.com · Manual · 2018-01-23 13:16:36.000000
Gil Fosh
· gilfosh@gmail.com · Manual · 2018-01-23 13:16:36.000000
Gil Fosh
· gilfosh@gmail.com · Manual · 2018-01-23 13:16:36.000000
Gil Fosh
· gilfosh@gmail.com · Manual · 2018-01-23 13:16:36.000000
Gil Fosh
· gilfosh@gmail.com · Manual · 2018-01-23 13:16:36.000000
Gil Fosh
· gilfosh@gmail.com · Manual · 2018-01-23 13:14:25.000000
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 69/100 |
| Missing | product stage, sector, founding month, business model, funding rounds, markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Crunchbase | west-pharmaceutical-services-inc |
| Phone | +97297778666 (Medimop) |
| Creator | Yamila Silbert |
| Creator email | yamila.urwicz@gmail.com |
| Last updater | Maor Perlov |
| Updater email | maor.perlov@sncentral.org |
| Last update | 2023-05-12T00:00:00.000Z |
| Created | 2016-08-29T00:00:00.000Z |
| Status detail | Public on NYSE on Jan, 1978; |